Etanercept
證據等級: L5 | 預測適應症: 6 個
## 藥師評估報告
Etanercept 藥師評估筆記
一句話總結
Etanercept 是一種 TNF-alpha 抑制劑，TxGNN 預測其可能用於多種神經退化性疾病，但目前缺乏臨床試驗支持。
快速總覽
| 項目 | 內容 |
|---|---|
| 藥物名稱 | Etanercept (恩博) |
| DrugBank ID | DB00005 |
| 台灣商品名 | 爾瑞易注射液 |
| 原核准適應症 | 類風濕性關節炎、乾癬性關節炎、僵直性脊椎炎、中重度乾癬 |
| 預測新適應症 | ankylosing spondylitis、rheumatoid vasculitis、hypermobility of coccyx、inflammatory spondylopathy、spondyloarthropathy, susceptibility to、Kummell disease |
| 最高預測分數 | 0.9986 (primary progressive multiple sclerosis) |
| 證據等級 | L5 (僅預測) |
預測適應症詳細分析
1. rheumatoid vasculitis L2 99.71% 主要分析
為什麼這個預測合理？
Etanercept 透過抑制 TNF-alpha 發揮免疫調節作用。TNF-alpha 在神經退化性疾病中的角色已被廣泛研究：
- 發炎機轉關聯：TNF-alpha 參與中樞神經系統的發炎反應，而神經發炎是多發性硬化症和視神經脊髓炎的重要病理機制
- 血腦屏障通透性：TNF-alpha 可增加血腦屏障通透性，理論上抑制 TNF-alpha 可能減少神經損傷
- 免疫調節重疊：Etanercept 已核准用於多種自體免疫疾病，這些疾病與神經自體免疫疾病有部分機轉重疊
然而需注意：Etanercept 為大分子生物製劑，難以穿透血腦屏障，這對中樞神經系統疾病的治療構成挑戰。
臨床試驗
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT02590562 | N/A | COMPLETED | 808 | A Multi-center Cross-sectional Study on Treatment Patterns and Patient Character... |
| NCT01579006 | N/A | COMPLETED | 184 | A Multi National, Multi-center Non-interventional Study in Rheumatoid Arthritis ... |
| NCT00001901 | PHASE2 | COMPLETED | 60 | Phase I/II Trial of TNFR:Fc (Etanercept) in Patients With Wegener's Granulomatos... |
| NCT01557322 | N/A | COMPLETED | 1754 | Evaluation of the Clinical Characteristics, Real-world Treatment Pathways, and O... |
| NCT07138898 | PHASE2 | NOT_YET_RECRUITING | 80 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total ... |
| NCT05696106 | N/A | UNKNOWN | 750000 | Risk of Incident Immune-mediated Inflammatory Diseases (IMID) in Patients Treate... |
相關文獻
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 33058033 | 2021 | Article | Clinical rheumatology | Biological therapy in rheumatoid vasculitis: a systematic review. |
| 28391344 | 2017 | Article | Nephrology, dialysis, transpla | Is there a role for TNFα blockade in ANCA-associated vasculitis and glomerulonep... |
| 31668853 | 2019 | Article | Biologicals : journal of the I | Efficacy and safety of original and biosimilar etanercept (SB4) in active rheuma... |
| 31632872 | 2019 | Article | Cureus | Etanercept-associated Nephropathy. |
| 15468348 | 2004 | Article | The Journal of rheumatology | Tumor necrosis factor-alpha blockade and the risk of vasculitis. |
| 12209493 | 2002 | Article | Arthritis and rheumatism | Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid... |
| 38931826 | 2024 | Article | Pharmaceutics | Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimen... |
| 15624748 | 2004 | Article | Journal of drugs in dermatolog | The medical uses and side effects of etanercept with a focus on cutaneous diseas... |
| 28123776 | 2017 | Article | RMD open | Drug-specific risk and characteristics of lupus and vasculitis-like events in pa... |
| 10955351 | 2000 | Article | The Journal of rheumatology | Leukocytoclastic vasculitis due to etanercept. |
| 31491879 | 2019 | Article | International journal of molec | Different Original and Biosimilar TNF Inhibitors Similarly Reduce Joint Destruct... |
| 24854356 | 2014 | Article | Annals of the rheumatic diseas | What is the utility of routine ANA testing in predicting development of biologic... |
| 11792895 | 2002 | Article | Rheumatology (Oxford, England) | Etanercept and infliximab associated with cutaneous vasculitis. |
| 15627197 | 2006 | Article | Rheumatology international | Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity. |
| 19648728 | 2009 | Article | Dermatology (Basel, Switzerlan | Disseminated herpes zoster mimicking rheumatoid vasculitis in a rheumatoid arthr... |
| 17657687 | 2007 | Article | Scandinavian journal of rheuma | Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept ther... |
| 25544845 | 2014 | Article | Case reports in medicine | Large Vessel Vasculitis Occurring in Rheumatoid Arthritis Patient under Anti-TNF... |
| 15853915 | 2005 | Article | Scandinavian journal of immuno | Immunology of cutaneous vasculitis associated with both etanercept and inflixima... |
| 15801034 | 2005 | Article | The Journal of rheumatology | Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment w... |
| 23154729 | 2012 | Article | Internal medicine (Tokyo, Japa | Foot ulcers caused by rheumatoid vasculitis in a patient with rheumatoid arthrit... |
2. hypermobility of coccyx L5 99.63%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
3. inflammatory spondylopathy L1 99.57%
臨床試驗（50 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT02509026 | PHASE4 | COMPLETED | 210 | A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJE... |
| NCT02376790 | PHASE3 | COMPLETED | 851 | A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methot... |
| NCT03729674 | N/A | UNKNOWN | 800 | Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs |
| NCT05164198 | PHASE4 | UNKNOWN | 448 | Multicenter, Prospective Clinical Trial for Optimizing TNF Inhibitor Dose Adjust... |
| NCT01934933 | PHASE4 | COMPLETED | 150 | A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Al... |
| NCT01604629 | PHASE4 | COMPLETED | 120 | Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Pati... |
| NCT00133315 | PHASE4 | COMPLETED | 50 | TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study ... |
| NCT00432406 | PHASE4 | COMPLETED | 40 | TNF-α Blockade for Psoriatic Arthritis - A Clinical and MRI Study, and the Effec... |
| NCT00247962 | PHASE4 | COMPLETED | 566 | A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercep... |
| NCT00244179 | PHASE2 | UNKNOWN | 40 | New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis: Immunosti... |
| NCT05080218 | PHASE4 | COMPLETED | 841 | The SARS-CoV-2 Vaccine Response and Safety in Rheumatology Patients and the Infl... |
| NCT01258738 | PHASE3 | COMPLETED | 225 | A Multicentre, 12 Week Double Blind Placebo Controlled Randomized Study Of Etane... |
| NCT00273858 | N/A | TERMINATED | 880 | Open Label Study To Evaluate The Safety Profile And The Quality Of Life In Patie... |
| NCT00224562 | N/A | UNKNOWN | N/A | The RATIO Registry: French Registry on Opportunistic and Severe Bacterial Infect... |
| NCT00127842 | PHASE4 | COMPLETED | 110 | Rating Evaluations in Psoriatic Arthritis (PsA) With Enbrel® |
| NCT02638896 | PHASE4 | UNKNOWN | 100 | Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spo... |
| NCT00508547 | N/A | ACTIVE_NOT_RECRUITING | 15842 | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidate... |
| NCT05115903 | PHASE4 | UNKNOWN | 15 | A Prospective, Randomized Biologic Tapering Study of TNF Inhibitors in Axial Spo... |
| NCT04077957 | PHASE4 | UNKNOWN | 100 | Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventi... |
| NCT00410046 | PHASE4 | COMPLETED | 84 | An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subje... |
| NCT00293722 | N/A | COMPLETED | 1308 | Prospective Post Marketing Surveillance to Evaluate the Safety and Efficacy of E... |
| NCT01060098 | N/A | COMPLETED | 48 | T Cells and TNF: The Impact of TNF Blockade on Effector T Cell Populations in Rh... |
| NCT01793285 | N/A | COMPLETED | 85 | Retrospective, Multicentric, National, Observational Study, to Follow-up the Pat... |
| NCT04582084 | N/A | COMPLETED | 583 | Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanerc... |
| NCT06085079 | PHASE4 | UNKNOWN | 20 | A 24-week Two-armed Proof-of-concept Exploratory Analysis of Subcutaneous Ixekiz... |
| NCT07041112 | N/A | COMPLETED | 1000 | Pharmacogenetic Observational Study Evaluating the Influence of Genetic Variants... |
| NCT00356356 | PHASE3 | COMPLETED | 257 | Open-label, Long-term Extension Study of Etanercept in the Treatment of Patients... |
| NCT03496831 | N/A | COMPLETED | 7500 | Development of a Prediction Model for the Risk of Hospitalized Infection in Pati... |
| NCT02915354 | PHASE4 | COMPLETED | 35 | Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical ... |
| NCT02809781 | PHASE2, PHASE3 | UNKNOWN | 250 | Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS |
| NCT04345458 | PHASE3 | COMPLETED | 640 | Safety and Efficacy of Prefilled Liquid Etanercept(Yisaipu) for Active Ankylosin... |
| NCT00420238 | PHASE4 | COMPLETED | 82 | A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept ... |
| NCT04891640 | NA | ACTIVE_NOT_RECRUITING | 164 | Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile ... |
| NCT04610476 | PHASE3 | UNKNOWN | 270 | A Prospective, Randomized, Controlled, Open Label, Assessor-blinded, Parallel-gr... |
| NCT04428502 | N/A | COMPLETED | 127 | Correlation of Anti-CCP With Disease Activity and Its Impact on Biological Respo... |
| NCT03100734 | N/A | COMPLETED | 585 | A Multicentre Observational Study to Evaluate the Real-Life Effectiveness of Ben... |
| NCT00910273 | PHASE4 | TERMINATED | 34 | Effects of Etanercept on Endothelial Function and Carotid Intima-media Thickness... |
| NCT02456363 | PHASE2 | UNKNOWN | 300 | Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis-A Reg... |
| NCT03470688 | N/A | UNKNOWN | 5000 | An Observational Study Designed to Investigate the Utilisation and Effectiveness... |
| NCT02489760 | PHASE4 | UNKNOWN | 30 | Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondy... |
| NCT00478660 | PHASE3 | COMPLETED | 1250 | Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing... |
| NCT00195416 | N/A | COMPLETED | 526 | A Drug Use Investigation of Enbrel for Post-marketing Surveillance (PMS) for Ank... |
| NCT01965132 | N/A | RECRUITING | 10000 | Korean College of Rheumatology Biologics and Targeted Therapy Registry |
| NCT03504072 | PHASE4 | UNKNOWN | 174 | Risk of Tuberculosis and Infections in Spondyloarthritis Patients Treated With T... |
| NCT00678782 | PHASE2 | COMPLETED | 31 | Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients ... |
| NCT00421915 | PHASE3 | COMPLETED | 84 | Multicenter, Double-Blind, Parallel, Placebo-Controlled, Randomised Phase 3 Stud... |
| NCT01411215 | N/A | TERMINATED | 160 | A Non-Interventional Study of the Treatment With Etanercept in Rheumatoid Arthri... |
| NCT01465438 | PHASE4 | COMPLETED | 42 | Can New Imaging- and Biomarkers Improve the Assessment of Disease Activity and P... |
| NCT00844142 | PHASE2 | UNKNOWN | 80 | Randomized Controlled 12 Months Trial With Etanercept (Enbrel ®) vs. Sulfasalazi... |
| NCT01610947 | NA | COMPLETED | 398 | Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease A... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 25438042 | 2015 | Article | Current medical research and o | Etanercept and uveitis: friends or foes? |
| 24980068 | 2015 | Article | Rheumatology international | Etanercept biosimilars. |
| 28940172 | 2017 | Article | BioDrugs : clinical immunother | GP2015: An Etanercept Biosimilar. |
| 17072572 | 2006 | Article | Zeitschrift fur Rheumatologie | [Spondylarthritides]. |
| 28837372 | 2018 | Article | Modern rheumatology | Update upon efficacy and safety of etanercept for the treatment of spondyloarthr... |
| 28682112 | 2017 | Article | Expert opinion on biological t | Etanercept for treating axial spondyloarthritis. |
| 36752358 | 2023 | Article | Arthritis care & research | Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and ... |
| 18208819 | 2008 | Article | Rheumatology (Oxford, England) | Infliximab, etanercept and adalimumab for the treatment of ankylosing spondyliti... |
| 28752242 | 2017 | Article | BioDrugs : clinical immunother | Patients' Understanding and Attitudes Towards Infliximab and Etanercept Biosimil... |
| 28434410 | 2017 | Article | International journal of techn | DOSAGE AND DURATION OF ETANERCEPT THERAPY FOR ANKYLOSING SPONDYLITIS: A META-ANA... |
| 16097922 | 2005 | Article | The Medical journal of Austral | Tumour necrosis factor inhibitors. |
| 36379575 | 2023 | Article | The Journal of rheumatology | Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis... |
| 35434764 | 2022 | Article | Clinical rheumatology | Clinical efficacy and safety of adalimumab versus etanercept in patients with an... |
| 17651658 | 2007 | Article | Health technology assessment ( | Adalimumab, etanercept and infliximab for the treatment of ankylosing spondyliti... |
| 31483969 | 2019 | Article | The New England journal of med | A Terminal Event. |
| 15161337 | 2004 | Article | BioDrugs : clinical immunother | Etanercept: in ankylosing spondylitis. |
| 25910480 | 2015 | Article | International journal of clini | Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in... |
| 35234569 | 2023 | Article | Scandinavian journal of rheuma | Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondyli... |
| 39734351 | 2024 | Article | Turkish journal of medical sci | The relationship between drug-induced immunogenicity and hypersensitivity reacti... |
| 35777821 | 2023 | Article | The Journal of rheumatology | Inflammatory Bowel Disease Risk in Patients With Axial Spondyloarthritis Treated... |
4. Kummell disease L5 99.55%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
5. polyarticular juvenile rheumatoid arthritis L1 99.50%
臨床試驗（8 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT06654882 | PHASE3 | NOT_YET_RECRUITING | 400 | Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthri... |
| NCT01145352 | N/A | COMPLETED | 113 | Enbrel-JIA Use Results Survey [All-Case Surveillance] |
| NCT03780959 | PHASE2, PHASE3 | COMPLETED | 69 | Safety, Population Pharmacokinetics, and Efficacy of Recombinant Human Tumor Nec... |
| NCT03781375 | PHASE3 | TERMINATED | 25 | A Phase III Double Blind Randomized Study Comparing Etanercept (Enbrel) Combined... |
| NCT06413563 | N/A | NOT_YET_RECRUITING | 75 | Analysis of Peripheral Blood Lymphocytes in Patients With Juvenile Idiopathic Ar... |
| NCT00078793 | N/A | COMPLETED | 600 | Phase IV Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid A... |
| NCT07386587 | PHASE3 | ENROLLING_BY_INVITATION | 60 | Response of Methotrexate Alone Versus Methotrexate Combined With Etanercept for ... |
| NCT02840175 | PHASE3 | COMPLETED | 62 | Treatment Tapering in Oligoarticular or Rheumatoid Factor Negative Polyarticular... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 28418334 | 2017 | Article | Balkan medical journal | Juvenile Idiopathic Arthritis. |
| 26233720 | 2015 | Article | Clinical rheumatology | Enthesitis-related arthritis. |
| 40148850 | 2025 | Article | BMC pediatrics | Comparative efficacy and safety of etanercept and adalimumab in the treatment of... |
| 29781829 | 2019 | Article | Journal of clinical rheumatolo | Comparison of Adults With Polyarticular Juvenile Idiopathic Arthritis to Adults ... |
| 12641492 | 2003 | Article | BioDrugs : clinical immunother | Spotlight on etanercept in rheumatoid arthritis, psoriatic arthritis and juvenil... |
| 27989499 | 2016 | Article | Seminars in arthritis and rheu | Biological agents in polyarticular juvenile idiopathic arthritis: A meta-analysi... |
| 38204313 | 2023 | Article | The Turkish journal of pediatr | Choice and switch of biologic drugs in juvenile idiopathic arthritis. |
| 10717011 | 2000 | Article | The New England journal of med | Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatr... |
| 11302411 | 2001 | Article | The Annals of pharmacotherapy | Etanercept in juvenile rheumatoid arthritis. |
| 12421111 | 2002 | Article | Drugs | Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arth... |
| 11246677 | 2001 | Article | The Journal of rheumatology | Clinical response to etanercept in polyarticular course juvenile rheumatoid arth... |
| 28025136 | 2017 | Article | Clinical immunology (Orlando, | CD3+CD56+ natural killer T cell activity in children with different forms of juv... |
| 39946290 | 2025 | Article | Expert opinion on drug safety | An update on the safety of biologic therapies for the treatment of polyarticular... |
| 17563271 | 2007 | Article | Expert opinion on pharmacother | Etanercept: long-term clinical experience in rheumatoid arthritis and other arth... |
| 10595864 | 1999 | Article | Drugs | Medical management of children with juvenile rheumatoid arthritis. |
| 11773549 | 2002 | Article | Pediatrics | Current treatment of juvenile rheumatoid arthritis. |
| 20444859 | 2010 | Article | Rheumatology (Oxford, England) | Etanercept improves linear growth and bone mass acquisition in MTX-resistant pol... |
| 11583059 | 2001 | Article | Expert opinion on pharmacother | The treatment of juvenile arthritis. |
| 20087751 | 2010 | Article | Modern rheumatology | Guidelines on the use of etanercept for juvenile idiopathic arthritis in Japan. |
| 24599916 | 2014 | Article | Rheumatology (Oxford, England) | Predictors of response to etanercept in polyarticular-course juvenile idiopathic... |
6. vertebral disease L1 99.16%
臨床試驗（6 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT01258738 | PHASE3 | COMPLETED | 225 | A Multicentre, 12 Week Double Blind Placebo Controlled Randomized Study Of Etane... |
| NCT05115903 | PHASE4 | UNKNOWN | 15 | A Prospective, Randomized Biologic Tapering Study of TNF Inhibitors in Axial Spo... |
| NCT02809781 | PHASE2, PHASE3 | UNKNOWN | 250 | Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS |
| NCT00413400 | NA | COMPLETED | 40 | Effects of Etanercept in Patients With the Metabolic Syndrome (II) |
| NCT01188655 | N/A | COMPLETED | 89 | Observational Non-Interventional Study With Enbrel in Patients With Ankylosing S... |
| NCT01400516 | PHASE4 | COMPLETED | 26 | Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 31969328 | 2020 | Article | Annals of the rheumatic diseas | EULAR recommendations for the management of rheumatoid arthritis with synthetic ... |
| 38503473 | 2024 | Article | Annals of the rheumatic diseas | Efficacy and safety of pharmacological treatment of psoriatic arthritis: a syste... |
| 17072572 | 2006 | Article | Zeitschrift fur Rheumatologie | [Spondylarthritides]. |
| 28682112 | 2017 | Article | Expert opinion on biological t | Etanercept for treating axial spondyloarthritis. |
| 35543102 | 2023 | Article | Scandinavian journal of rheuma | Does a short course of etanercept influence disease progression and radiographic... |
| 24101863 | 2013 | Article | Patient preference and adheren | Long-term safety and efficacy of etanercept in the treatment of ankylosing spond... |
| 20554241 | 2010 | Article | Joint bone spine | Elderly-onset rheumatoid arthritis. |
| 29624303 | 2016 | Article | Reumatizam | [JUVENILE SPONDYLOARTHRITIS]. |
| 31483969 | 2019 | Article | The New England journal of med | A Terminal Event. |
| 16310398 | 2005 | Article | Joint bone spine | Psoriatic arthritis. |
| 32007648 | 2020 | Article | Joint bone spine | Chronic bursitis and tenosynovitis revealing Whipple's disease. |
| 36633815 | 2023 | Article | Rheumatology and therapy | Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-... |
| 31749988 | 2019 | Article | RMD open | Treatment retention of infliximab and etanercept originators versus their corres... |
| 38309516 | 2024 | Article | Joint bone spine | Targeted therapies for uveitis in spondyloarthritis: A narrative review. |
| 28482137 | 2017 | Article | Arthritis care & research | Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Sig... |
| 26560086 | 2015 | Article | Alzheimer's research & therapy | Central delivery of iodine-125-labeled cetuximab, etanercept and anakinra after ... |
| 20444859 | 2010 | Article | Rheumatology (Oxford, England) | Etanercept improves linear growth and bone mass acquisition in MTX-resistant pol... |
| 24891317 | 2014 | Article | Arthritis & rheumatology (Hobo | Symptomatic efficacy of etanercept and its effects on objective signs of inflamm... |
| 40015358 | 2025 | Article | Joint bone spine | Clinical and ultrasonographic predictors of disease activity after TNF-α inhibit... |
| 34838991 | 2022 | Article | Joint bone spine | Changes in etanercept and adalimumab biosimilar prescriptions for the initial tr... |
台灣上市資訊
| 項目 | 內容 |
|---|---|
| 許可證字號 | 衛署菌疫輸字第000876號 |
| 中文品名 | 爾瑞易注射液 |
| 英文品名 | Enbrel Solution for Injection |
| 許可證持有者 | 輝瑞大藥廠股份有限公司 |
| 劑型 | 注射劑 |
| 核准日期 | 2012/03/26 |
| 有效期限 | 2027/03/26 |
| 狀態 | 有效 |
安全性考量
已知風險
- 感染風險增加：包括嚴重細菌、病毒、真菌感染
- 結核病再活化：使用前需篩檢潛伏性結核
- 惡性腫瘤風險：長期使用可能增加淋巴瘤風險
- 注射部位反應：常見局部反應
藥物交互作用
根據 DDInter 資料庫，Etanercept 與以下藥物有交互作用：
- Anakinra (Major)：不建議併用，增加嚴重感染風險
- Abatacept (Major)：不建議併用
- 活疫苗：禁止併用
特殊族群
- 孕婦：C 級，權衡利弊後使用
- 哺乳：少量分泌至乳汁
- 肝腎功能不全：無需調整劑量
藥物-草藥交互作用 (DHI)
紫錐花 🟡 Moderate
- 影響：紫錐花可能與免疫調節藥物產生交互作用
- 建議：謹慎使用
結論與下一步
整體評估
此預測目前不建議臨床應用，原因如下：
- 缺乏任何臨床試驗或觀察性研究支持
- Etanercept 為大分子藥物，中樞神經系統滲透性差
- 部分預測適應症(如 MS)實際上可能因 TNF 抑制而惡化
建議行動
- 需要更多基礎研究探討 TNF-alpha 抑制在神經退化性疾病中的角色
- 若要進行臨床研究，需先解決藥物遞送至中樞神經系統的問題
- 密切監測已使用 Etanercept 患者是否出現神經系統症狀
風險等級
高風險 - 不建議超適應症使用
報告生成日期：2026-02-11 資料來源：TxGNN 預測、ClinicalTrials.gov、PubMed、TFDA
相關藥物報告
- Homatropine Methylbromide - 證據等級 L5
- Nitrofurantoin - 證據等級 L5
- Urea - 證據等級 L5
- Vigabatrin - 證據等級 L5
- Bevacizumab - 證據等級 L5
用 AI 幫我深入分析
想進一步了解這個藥物的老藥新用潛力嗎？點擊下方按鈕，直接開啟 AI 助手進行分析。
Claude：點擊後會複製提問並開啟新視窗，請按 Ctrl+V（Mac: Cmd+V）貼上
ChatGPT：點擊後直接開啟並自動帶入提問
引用本報告
如需引用本報告，請使用以下格式：
APA 格式：
TwTxGNN. (2026). Etanercept老藥新用驗證報告. https://twtxgnn.yao.care/drugs/etanercept/
BibTeX 格式：
@misc{twtxgnn_etanercept,
title = {Etanercept老藥新用驗證報告},
author = {TwTxGNN Team},
year = {2026},
url = {https://twtxgnn.yao.care/drugs/etanercept/}
}
免責聲明
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
歡迎分享您對本報告的看法、補充資訊或提出問題。討論內容會同步到 GitHub Discussions。 需要 GitHub 帳號才能留言。